SBU assess relevant and well-conducted research and investigate what effect different interventions have, if there are any risks or ethical problems, and what is most cost-effective in the areas of health care, dentistry, social services, and within the areas of functional disability and work environment.
Liquid biopsy is a diagnostic method that allows to identify and measure very small amounts of free DNA or RNA sequences in body fluids, such as blood. The technique is considered precise enough that it could be used to detect and diagnose malignant tumors before the appearance of any symptoms, but also develop into an important marker for follow-up of different therapies. The method has developed rapidly and could within a near future be subject for clinical introduction.
The aim of this project is to study the accurary of liquid biopsies in detecting early, asymptomatic ovarian cancer. Early diagnostics of ovarian cancer are of particular interest as the prognose is heavily dependent on when the disease is discovered. If detected early the prognosis is often good. If, however, detected late the prognosis is considerably worse and altogether presents a significantly more complex condition to treat. Today most cases of ovarian cancer are diagnosed at a late stage.
Recruitment is currently ongoing.
- Jan Holst, Project Manager
- Helena Domeij, Assistant Project Manager
- Caroline Jungner, Project Administrator
- Ann Kristine Jonsson, Information Specialist
- Therese Eriksson, Health Economist
- Jenny Odeberg, Head of Department